Ravulizumab
Ravulizumab is an eight-weekly infusion that blocks the complement system; it treats paroxysmal nocturnal haemoglobinuria, a clonal bone marrow disorder managed by haematologists alongside aplastic anaemia and myelodysplasia.
Overview
Ravulizumab is a re-engineered, longer-acting successor to eculizumab that blocks complement C5. The United States approved it in 2018 for paroxysmal nocturnal haemoglobinuria (PNH), an acquired clonal disorder of blood stem cells in which complement destroys red cells, and then for atypical haemolytic uraemic syndrome and generalised myasthenia gravis. PNH is not a cancer but arises from the same stem-cell compartment as myelodysplastic syndromes and often follows aplastic anaemia, so it sits within the haematology and bone marrow failure workload of cancer centres. Complement blockade is also being tested for transplant-associated thrombotic microangiopathy after stem cell transplantation. Meningococcal infection risk requires vaccination before treatment.
Binds complement protein C5 and prevents its cleavage into C5a and C5b, so the membrane attack complex cannot form and complement-driven destruction of blood cells stops.
1.Ravulizumab binds its target.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2018 | Paroxysmal nocturnal haemoglobinuria · Later extended to atypical haemolytic uraemic syndrome and generalised myasthenia gravis |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Ravulizumab" OR ABSTRACT:"Ravulizumab" OR TITLE:"Ultomiris" OR ABSTRACT:"Ultomiris" OR TITLE:"Ravulizumab-cwvz" OR ABSTRACT:"Ravulizumab-cwvz" OR TITLE:"ALXN1210" OR ABSTRACT:"ALXN1210") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ravulizumab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentEltrombopag
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tags gap-fill, supportive-care.
- TreatmentRomiplostim
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tags gap-fill, supportive-care.
- TreatmentEmapalumab
Shares the tags gap-fill, supportive-care.
- TreatmentFostamatinib
Shares the tags gap-fill, supportive-care.
- TreatmentPropranolol (Hemangeol)
Shares the tags gap-fill, supportive-care.
- TreatmentMoxetumomab pasudotox
Shares AstraZeneca and the tag gap-fill.
- TreatmentLuspatercept
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag gap-fill.
- TreatmentImetelstat
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag gap-fill.